Results 101 to 110 of about 387,299 (303)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases

Frontiers in Endocrinology, 2020
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in the liver.
Erik J. Tillman, T. Rolph
semanticscholar   +1 more source

PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis [PDF]

, 2017
Background & Aims: Mitochondria) dysfunction, oxidative stress, inflammation, and metabolic reprograming are crucial contributors to hepatic injury and subsequent liver fibrosis.
Varga, Zoltan V., Liaudet, Lucas, Cao, Z., Bai, P., Xu, Ming-Jiang, Wang, Wei, Gao, B., Rajesh, M., Pacher, P., Mukhopadhyay, Partha, Gao, Bin, Auwerx, Johan, Mukhopadhyay, P., Nemeth, Balazs Tamas, Persidsky, Yuri, Pacher, Pal, Haskó, G., Cao, Zongxian, Park, Ogyi, Persidsky, Y., Zhou, Z., Horvath, Bela, Holovac, Eileen, Zhou, Zhou, Gariani, K., Horváth, B., Liaudet, L., Gariani, Karim, Auwerx, J., Godlewski, Grzegorz, Park, O., Xu, M.J., Rajesh, Mohanraj, Ryu, Dongryeol, Godlewski, G., Bai, Peter, Ryu, D., Holovac, E., Paloczi, Janos, Paloczi, J., Boulares, A. Hamid, Varga, Z.V., Wang, W., Nemeth, B.T., Boulares, A.H., Hasko, Gyorgy   +45 more
core   +1 more source

Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist

, 2023
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of fat-associated liver conditions that increase risk of cardiovascular disease and mortality. The diagnosis and clinical management of NAFLD remain a challenge for cardiologists.
Caballero-Valderrama, María de Regla, Barón-Esquivias, Gonzalo, Palacios Castelló Carlos, Millán-Rodríguez Carlos   +3 more
core   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Marcadores genéticos do MHC-Classe I na esteatohepatite não alcoólica [PDF]

, 2009
Mestrado em Biologia Molecular e CelularO Fígado é o principal órgão regulador do metabolismo do ferro. Distúrbios relacionados com a sobrecarga de ferro podem ser devido a factores genéticos, como na HH com mutações conhecidas para o gene HFE, mas ...
Costa, Mónica Isabel Encarnação
core  

Analysis of the effects of xanthohumol on hepatic homeostasis, inflammation, fibrosis and cancerogenesis [PDF]

, 2009
Xanthohumol is the major prenylated chalcone found in hops, and it has been shown to exhibit various biological effects. However, xanthohumol effects on liver cells or in liver diseases, respectively, are widely unknown.
Dorn, Christoph Michael
core   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

Scientific Reports, 2021
Psoriasis and non-alcoholic fatty liver disease (NAFLD) are both inflammatory diseases. The study objective was to estimate the risk of NAFLD, non-alcoholic steatohepatitis, and liver fibrosis (by liver stiffness and liver biopsy) in patients with ...
Isabel Belinchón-Romero, Pablo Bellot, David Romero-Pérez, Isolina Herraiz-Romero, Francisco Marco, Rubén Frances, José-Manuel Ramos-Rincón   +6 more
doaj   +1 more source

Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics, 2020
Non‐alcoholic steatohepatitis (NASH) is a severe form of non‐alcoholic fatty liver disease (NAFLD) characterised by liver fat accumulation, inflammation and progressive fibrosis. Emerging data indicate that genetic susceptibility increases risks of NAFLD,
B. Carlsson, D. Lindén, Gabriella Brolén, M. Liljeblad, Mikael Bjursell, S. Romeo, R. Loomba   +6 more
semanticscholar   +1 more source

Microbial Interventions in Processing of Plant Based Proteins: Unlocking Extraction Dynamics and Functionality for Human Health

Food Bioengineering, EarlyView.
Fermentation enhances nutritional & techno‐functional properties of plant protein. Three distinct stages of fermentation impact on different aspects of plant protein. Fermentation induces flavors modulation through new organic compounds formation. Plant protein fermentation improves their utility in food applications.
Disha, Mitali Madhumita, Dharmender Kumar, Pramod Kumar Prabhakar   +3 more
wiley   +1 more source